STIM Stock Overview
A commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Neuronetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.75 |
| 52 Week High | US$5.07 |
| 52 Week Low | US$1.03 |
| Beta | 2.32 |
| 11 Month Change | -8.85% |
| 3 Month Change | -61.45% |
| 1 Year Change | -21.17% |
| 33 Year Change | -88.07% |
| 5 Year Change | -86.02% |
| Change since IPO | -93.70% |
Recent News & Updates
Here's Why Shareholders May Want To Be Cautious With Increasing Neuronetics, Inc.'s (NASDAQ:STIM) CEO Pay Packet
May 24
The Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 09Neuronetics: Reality Set In
May 09Recent updates
Here's Why Shareholders May Want To Be Cautious With Increasing Neuronetics, Inc.'s (NASDAQ:STIM) CEO Pay Packet
May 24The Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 09Neuronetics: Reality Set In
May 09Market Cool On Neuronetics, Inc.'s (NASDAQ:STIM) Revenues Pushing Shares 36% Lower
May 08Neuronetics (NASDAQ:STIM) Has Debt But No Earnings; Should You Worry?
May 01Even With A 26% Surge, Cautious Investors Are Not Rewarding Neuronetics, Inc.'s (NASDAQ:STIM) Performance Completely
Mar 17Neuronetics: Modest Improvements Are Not Enough
Jan 30Neuronetics, Inc. (NASDAQ:STIM) Soars 61% But It's A Story Of Risk Vs Reward
Dec 19Neuronetics, Inc.'s (NASDAQ:STIM) Shares Not Telling The Full Story
Jun 21Does Neuronetics (NASDAQ:STIM) Have A Healthy Balance Sheet?
May 10Neuronetics: Growth To Capture, But Fairly Priced
Sep 06Is Neuronetics (NASDAQ:STIM) Using Debt Sensibly?
Sep 06Neuronetics gets FDA nod for its D-Tect accessory product for use to treat depression
Aug 29Neuronetics GAAP EPS of -$0.39 beats by $0.02, revenue of $16.3M beats by $0.84M , revises FY guidance
Aug 02Neuronetics stock soars 30% as FDA clears NeuroStar system for anxious depression
Jul 19Is Neuronetics (NASDAQ:STIM) A Risky Investment?
Jun 08Is Neuronetics (NASDAQ:STIM) Weighed On By Its Debt Load?
Jan 19Shareholder Returns
| STIM | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -1.1% | -0.9% | 0.5% |
| 1Y | -21.2% | -2.6% | 20.5% |
Return vs Industry: STIM underperformed the US Medical Equipment industry which returned -1.4% over the past year.
Return vs Market: STIM underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| STIM volatility | |
|---|---|
| STIM Average Weekly Movement | 12.0% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: STIM's share price has been volatile over the past 3 months.
Volatility Over Time: STIM's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 202 | Keith Sullivan | neurostar.com |
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.
Neuronetics, Inc. Fundamentals Summary
| STIM fundamental statistics | |
|---|---|
| Market cap | US$54.00m |
| Earnings (TTM) | -US$27.54m |
| Revenue (TTM) | US$73.23m |
0.7x
P/S Ratio-1.9x
P/E RatioIs STIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STIM income statement (TTM) | |
|---|---|
| Revenue | US$73.23m |
| Cost of Revenue | US$17.93m |
| Gross Profit | US$55.30m |
| Other Expenses | US$82.84m |
| Earnings | -US$27.54m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | 75.52% |
| Net Profit Margin | -37.61% |
| Debt/Equity Ratio | 214.9% |
How did STIM perform over the long term?
See historical performance and comparison